Casodex (bicalutamide) 150-MG monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: Results from two multicenter randomized trials at a median follow-up of 4 years

被引:123
作者
Iversen, P
Tyrrell, CJ
Kaisary, AV
Anderson, JB
Baert, L
Tammela, T
Chamberlain, M
Carroll, K
Gotting-Smith, K
Blackledge, GRP
机构
[1] Univ Copenhagen, Copenhagen, Denmark
[2] Plymouth Gen Hosp, Plymouth, Devon, England
[3] Royal Free Hosp, London NW3 2QG, England
[4] Royal Hallamshire Hosp, Sheffield S10 2JF, S Yorkshire, England
[5] Univ Hosp, Louvain, Belgium
[6] Tampere Univ Hosp, Tampere, Finland
[7] Austin & Repatriat Med Ctr, Melbourne, Vic, Australia
[8] Zeneca Pharmaceut, Macclesfield, Cheshire, England
关键词
D O I
10.1016/S0090-4295(98)00004-1
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objectives. To compare the efficacy, tolerability, and quality of life benefits of bicalutamide (Casodex) 150-mg/ day monotherapy and castration in previously untreated nonmetastatic (MO) advanced prostate cancer. Methods. A total of 480 patients with Stage T3/T4 nonmetastatic disease randomly received oral bicalutamide 150 mg/day or castration (either bilateral orchiectomy or goserelin acetate [Zoladex] 3.6 mg every 28 days) in a 2:1 ratio in two open multicenter studies (studies 306 and 307). The design of these studies was similar to allow a pooled analysis. Results. In the combined survival analysis, at median follow-up of 202 and 205 weeks in studies 306 and 307, respectively with 31% of the cases resulting in death, bicalutamide 150-mg monotherapy was statistically equivalent to castration; the risk of death from any cause was 7% less with bicalutamide than with castration (hazard ratio [HR] = 0.93). Data on time to treatment failure and objective progression could not be pooled, as results for these end points differed between the trials. In study 306, bicalutamide 150-mg monotherapy increased time to objective progression (HR = 0.58; P = 0.033) and treatment failure (HR = 0.66; P = 0.074), whereas in study 307, time to progression (HR = 1.35; P = 0.0471) and treatment failure (HR = 1.24; P = 0.097) favored castration. Bicalutamide therapy showed significant advantages over castration for both sexual interest (P = 0.029) and physical capacity (P = 0.046). Bicalutamide 150-mg monotherapy was well tolerated. Conclusions. Bicalutamide 150-mg monotherapy provides a similar survival outcome to castration in previously untreated patients with nonmetastatic advanced prostate cancer and confers statistically significant benefits over castration with respect to sexual interest and physical capacity. (C) 1998, Elsevier Science Inc. All rights reserved.
引用
收藏
页码:389 / 396
页数:8
相关论文
共 29 条
[1]  
[Anonymous], BR J UROL S2
[2]   A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer [J].
Bales, GT ;
Chodak, GW .
UROLOGY, 1996, 47 (1A) :38-43
[3]  
Blackledge GRP, 1997, EUR UROL, V31, P30
[4]   Flutamide versus orchidectomy in the treatment of metastatic prostate carcinoma [J].
Studer, UE .
EUROPEAN UROLOGY, 1997, 32 (04) :395-396
[5]   Double-blind, randomized study of primary hormonal treatment of stage D2 prostate carcinoma: Flutamide versus diethylstilbestrol [J].
Chang, A ;
Yeap, B ;
Davis, T ;
Blum, R ;
Hahn, R ;
Khanna, O ;
Fisher, H ;
Rosenthal, J ;
Witte, R ;
Schinella, R ;
Trump, D .
JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (08) :2250-2257
[6]   SINGLE-AGENT THERAPY WITH BICALUTAMIDE - A COMPARISON WITH MEDICAL OR SURGICAL CASTRATION IN THE TREATMENT OF ADVANCED PROSTATE CARCINOMA [J].
CHODAK, G ;
SHARIFI, R ;
KASIMIS, B ;
BLOCK, NL ;
MACRAMALLA, E ;
KENNEALEY, GT .
UROLOGY, 1995, 46 (06) :849-855
[7]   HEALTH-RELATED QUALITY-OF-LIFE IN PATIENTS WITH ADVANCED PROSTATE-CANCER - A MULTINATIONAL PERSPECTIVE [J].
CLEARY, PD ;
MORRISSEY, G ;
OSTER, G .
QUALITY OF LIFE RESEARCH, 1995, 4 (03) :207-220
[8]   MONOTHERAPY WITH NILUTAMIDE, A PURE NONSTEROIDAL ANTIANDROGEN, IN UNTREATED PATIENTS WITH METASTATIC CARCINOMA OF THE PROSTATE [J].
DECENSI, AU ;
BOCCARDO, F ;
GUARNERI, D ;
POSITANO, N ;
PAOLETTI, MC ;
COSTANTINI, M ;
MARTORANA, G ;
GIULIANI, L .
JOURNAL OF UROLOGY, 1991, 146 (02) :377-381
[9]  
DELLAPONTI U, 1997, BR J UROL S2, V80, P276
[10]  
FOSSA SD, 1994, SEMIN ONCOL, V21, P657